Invo Bioscience (NASDAQ:INVO) stock is rocketing higher on Wednesday alongside its earnings report for the fourth quarter of 2023.The healthcare services fertility company reported a net loss of $2 million during the quarter. That’s an improvement over its net loss of $2.8 million from the same period of the year prior.Revenue reported by Invo Bioscience comes in at $1.38 million for Q4 2023. That’s a massive 397% increase over its Q4 2022 revenue of $278,142.Invo Bioscience CEO Steve Shum said the followin ...

☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or For the transition period from to | --- | --- | --- | --- | --- | |---------------------------------------------------------|---------------------------------------|---------------------|------------------|------------------------------------| | Nevada | 001-39701 | | | 20-4036208 | | (State or other jurisdiction of incorporation | (Commission | | | (IRS Employee | | or organization) | File No.) | | | Identification No ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39701 INVO Bioscience, Inc. (Former name, former address and former fiscal year, if changed since la ...

INVO Bioscience, Inc. (NASDAQ:INVO) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Robert Blum - Investor Relations Steve Shum - Chief Executive Officer Mike Campbell - Chief Operating and Vice President, Business Development Andrea Goren - Chief Financial Officer Operator Good afternoon. And welcome, to the INVO Bioscience Second Quarter Fiscal Year 2023 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note thi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39701 INVO Bioscience, Inc. (Exact Name of Registrant as Specified in its Charter) | Nevada | 20-4036208 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39701 INVO Bioscience, Inc. (Exact Name of Registrant as Specified in its Charter) | Nevada | 20-4036208 ...

INVO Bioscience, Inc. (NASDAQ:INVO) Q4 2022 Earnings Conference Call April 17, 2023 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Steven Shum - Chief Executive Officer Andrea Goren - Chief Financial Officer Mike Campbell - Chief Operating Officer and Vice President, Business Development Conference Call Participants Joanne Lee - Maxim Group John Heerdink - Vista Partners Operator Hello and welcome to the INVO Bioscience Fourth Quarter and Fiscal Year 2022 Financial Results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Exact name of registrant as specified in Charter) | Nevada | 001-39701 | 20-4036208 | | --- | --- | --- | | (State or other jurisdiction of incorporation | (Commission | (IRS Employee | | or organization) | File No.) | Identification No.) | For the fiscal year ended December 31, 2022 5582 Broadcast Court Sarasota, Florida, 34240 or (Address ...

INVO Bioscience, Inc. (NASDAQ:INVO) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Robert Blum - Lytham Partners, IR Steven Shum - Chief Executive Officer Mike Campbell - Chief Operating Officer and VP, Business Development Andrea Goren - Chief Financial Officer Conference Call Participants John Heerdink - Vista Partners LLC Operator Good day. And welcome to the INVO Bioscience Reports on the Third Quarter 2022 Financial Results Call. All participants will be in listen-on ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 (Address of principal executive offices) (Zip Code) (978) 878-9505 (Registrant's telephone number, including area code) Not applicable OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________ ...